Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. More Details
Flawless balance sheet and fair value.
Share Price & News
How has Oyster Point Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OYST is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: OYST's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: OYST underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: OYST underperformed the US Market which returned 33% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Oyster Point Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StRead This Before Selling Oyster Point Pharma, Inc. (NASDAQ:OYST) Shares
4 months ago | Simply Wall StHere's Why We're Not Too Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Situation
5 months ago | Simply Wall StWhat Type Of Shareholders Make Up Oyster Point Pharma, Inc.'s (NASDAQ:OYST) Share Registry?
Is Oyster Point Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OYST ($12.05) is trading below our estimate of fair value ($291.09)
Significantly Below Fair Value: OYST is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OYST is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: OYST is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OYST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OYST is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3.1x).
How is Oyster Point Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OYST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OYST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OYST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OYST's revenue (62.2% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: OYST's revenue (62.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OYST is forecast to be unprofitable in 3 years.
How has Oyster Point Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OYST is currently unprofitable.
Growing Profit Margin: OYST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OYST is unprofitable, and losses have increased over the past 5 years at a rate of 46.9% per year.
Accelerating Growth: Unable to compare OYST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OYST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: OYST has a negative Return on Equity (-52.35%), as it is currently unprofitable.
How is Oyster Point Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: OYST's short term assets ($158.9M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: OYST's short term assets ($158.9M) exceed its long term liabilities ($248.0K).
Debt to Equity History and Analysis
Debt Level: OYST is debt free.
Reducing Debt: OYST had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OYST has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OYST has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 51.2% each year.
What is Oyster Point Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OYST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OYST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OYST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OYST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OYST's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Nau (46 yo)
Dr. Jeffrey Nau, also known as Jeff, Ph. D, M. M. S, has been President, Chief Executive Officer and Director at Oyster Point Pharma, Inc since October 2017. Dr. Nau served as Vice President of Clinical an...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD5.75M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.
Experienced Management: OYST's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: OYST's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Oyster Point Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Oyster Point Pharma, Inc.
- Ticker: OYST
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$340.792m
- Shares outstanding: 26.01m
- Website: https://www.oysterpointrx.com
Number of Employees
- Oyster Point Pharma, Inc.
- 202 Carnegie Center
- Suite 109
- New Jersey
- United States
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the Unite...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 22:40|
|End of Day Share Price||2021/09/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.